ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Verrica Pharmaceuticals (VRCA)
Verrica Pharmaceuticals stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$3.41▼ -0.29%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
46%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Verrica Pharmaceuticals in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Verrica Pharmaceuticals
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Verrica Pharmaceuticals a 46% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $2.93 and $3.82; in 9 out of 10, between $2.31 and $4.85. Estimated annual volatility is 76%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $75.2M
- 52-week high
- $9.82
- 52-week low
- $3.28
- Revenue (12 months)
- $30.3M
- Revenue growth (YoY)
- +370.2%
- Gross margin
- 90.3%
- Operating margin
- -33.6%
- Net margin
- -50.3%
- Return on equity
- -72.3%
- Free cash flow (12 months)
- $-9.0M
- Beta
- 1.50
What this means
ATLAS does not publish a fair value for VRCA right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks VRCA has traded between $3.28 and $9.82. Today it is 65.3% below that high and 4% above its low.
On the business: revenue grew 370.2% year over year; net margin is 50.3%.
Its beta is 1.50: it tends to move more than the market, both up and down.
About the company
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company focused on developing and commercializing clinician-administered treatments for skin diseases that require medical intervention.
Want to see everything about Verrica Pharmaceuticals?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Verrica Pharmaceuticals do?
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company focused on developing and commercializing clinician-administered treatments for skin diseases that require medical intervention.
What is the chance VRCA goes up next month?
46%: close to a coin flip. In half of the simulated outcomes, VRCA ends the month between $2.93 and $3.82.
How big is Verrica Pharmaceuticals and what is its P/E ratio?
Verrica Pharmaceuticals's market capitalization is $75.2M. We do not show a P/E because it has no positive earnings to base one on.
How volatile is VRCA?
ATLAS estimates annual volatility at 76%. In a typical month, half of the outcomes end between $2.93 and $3.82.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer